On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector, with healthcare stocks across the board performing strongly. The rally was particularly driven by AI Pharmaceuticals, medical services, and DRG/DIP segments, with companies like Shanghai Runda Medical Technology Co., Ltd. leading the charge, resulting in nearly ten stocks hitting their daily trading limits.
This upward momentum has been fueled in part by the emergence of DeepSeek, a company that is spearheading an AI transformation movement across China’s healthcare industry. Leading this charge is Hengrui Pharmaceuticals, which wasted no time after the Lunar New Year holiday to issue a directive mandating comprehensive integration of DeepSeek technology across its operations.
Hengrui Pharmaceuticals Leads the Charge in AI Adoption
Immediately following the holiday break, Hengrui Pharmaceuticals issued an internal notice signed by Chairman Sun Piaoyang, requiring all departments—from R&D to sales—to submit detailed AI application plans by February 25. The implementation of these plans is directly tied to managerial performance evaluations, underscoring the company’s commitment to leveraging AI to enhance operational efficiency.
The move reflects a broader industry trend where companies are either aiming to become pioneers in healthcare innovation by enhancing their professional models with DeepSeek or seeking to optimize workflows and reduce costs through AI integration. DeepSeek itself identifies eight distinct ways pharmaceutical firms can benefit from its technology, ranging from accelerating drug discovery to improving patient care.
Across the Industry: Diverse Approaches to AI Integration
While Hengrui’s approach is comprehensive, other companies are adopting tailored strategies to integrate DeepSeek into their operations. Innovent Biologics, for instance, has focused on creating a service-oriented information hub by integrating DeepSeek with its钉钉AI assistant and portal systems. This strategy aims to streamline internal processes and enhance decision-making efficiency.
Meanwhile, Winning Health Technology Group is pursuing an ambitious vision of “omni-channel empowerment”, embedding AI into every aspect of its operations. The company has launched products like the WiNGPT 2.8 medical large model and the WiNEX Copilot 2.1 assistant, both fully integrated with DeepSeek technology.
Industry-Wide Impact: Efficiency and Innovation
The rush to adopt AI reflects a growing recognition among healthcare providers that failing to embrace this technological wave could lead to marginalization in an increasingly competitive landscape. The potential benefits are substantial, with AI expected to drastically reduce the time and cost associated with drug development—potentially cutting research timelines by two-thirds and costs by as much as 99.5%.
DeepSeek’s integration into platforms like Hangzhou Kang Ming Information Technology Co., Ltd, trading under the banner of “ClouDr” and Beijing Airdoc Technology Co., Ltd. further highlights the technology’s versatility. By leveraging DeepSeek R1, these companies are enhancing data mining capabilities, improving chronic disease management efficiency, and elevating clinical decision-making through advanced medical knowledge graphs.
Conclusion: AI as a Strategic Imperative
As more companies follow in Hengrui’s footsteps, the healthcare sector is undergoing a transformative shift. The integration of DeepSeek technology is not merely an optional upgrade but a strategic imperative for firms seeking to remain competitive. This trend underscores the broader technological revolution reshaping China’s pharmaceutical and medical services industries, with AI at the forefront of innovation.-Fineline Info & Tech
Leave a Reply